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Background and Objectives: Compare the risk of relapse to heroin
and other illicit opioids among opioid‐dependent patients receiving
treatment with extended‐release naltrexone (XR‐NTX) or
buprenorphine‐naloxone (BP‐NLX).
Methods: Re‐analyzed data from a 12‐week multicenter,
open‐label, randomized treatment study with a subsequent
36‐week open‐label follow‐up study. All patients, N= 143, had
completed detoxification and received at least one dose of study
medication.
Results: Of 143 patients (72% men), mean age 36 years, 71
received XR‐NTX and 72 BP‐NLX. The risk of first relapse and the
risk of any relapse to heroin and other illicit opioids were both
significantly lower in the XR‐NTX group compared with the
BP‐NLX group (hazard ratio [HR], 0.46; 95% confidence interval
[CI], 0.28‐0.76; P= .002, and HR, 0.11; 95% CI, 0.04‐0.29;
P< .001, respectively) and (HR, 0.15; 95% CI, 0.09‐0.27;
P< .001 and HR, 0.05; 95% CI, 0.03‐0.09; P< .001,
respectively). There was a stable low risk of relapse among
participants receiving XR‐NTX in the follow‐up.
Discussion and Conclusions: Compared to BP‐NLX, patients on
XR‐NTX had a substantially reduced risk of relapse to illicit opioids
and showed a stable low risk of relapse over time in longer‐term
treatment.
Scientific Significance: Our data support XR‐NTX as a first‐line
treatment option for patients with opioid addiction both in short and
longer‐term treatment. This is the first European study showing that
XR‐NTX significantly reduces the risk of first and any relapse to
heroin use in opioid‐dependent patients compared to BP‐NLX. Our
data contradict previous data from the X:BOT study, showing no
significant difference in relapse risk between the groups in a
6‐month randomised controlled trial. (© 2021 Authors. The
American Journal on Addictions published by Wiley Periodicals
LLC on behalf of The American Academy of Addiction Psychiatry).
(Am J Addict 2021;30:453–460)
INTRODUCTION
Opioid dependence is considered a chronic relapsing
disorder that carries an increased risk of repeated intoxication
and overdose deaths.1 During the past decade, opioid use has
developed into a public health concern, with an estimated
16 million people worldwide experiencing this reverting
illness.2 Consequently, expanding access to addiction
treatment is an essential component of a comprehensive
response.3 The most widely used therapeutic modality for the
management of opioid addiction is opioid maintenance
treatment (OMT), including methadone and buprenorphine.
An alternative therapeutic approach to opioid dependence is
complete detoxification and induction to antagonist
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medication.4 A full opioid antagonist like naltrexone, both
injectable and implantable, offers pharmacological protection
against relapse, re‐dependence and overdose, and provides
abstinence‐motivated users with substantial cognitive relief
from relapse‐related thoughts.5,6 An extended‐release
naltrexone (XR‐NTX) injection lasts for 1 month, and two
recent studies have shown that XR‐NTX is largely
comparable with buprenorphine‐naloxone (BP‐NLX) in
treatment safety, effectiveness, and retention.7,8 In a
previous paper7, we found that the treatment with XR‐NTX
was noninferior to BP‐NLX based on days of use of illicit
opioids and the group proportion of the total number of
opioid‐negative UDTs under the predefined conditions.
Lee et al8 reported superiority for buprenorphine using the
time to first relapse of illicit opioid use as the primary
outcome. While the Norwegian participants were included
during all stages of detoxification, the US study included all
participants before detoxification.
Despite this difference in method, a comparison of
outcomes between the studies seems crucial for the
understanding and clinical importance of the findings.
The aim of this study was to perform a secondary analysis
looking at the time to first relapse to illicit opioid use among
abstinent‐motivated patients who successfully completed
detoxification, both in the randomized trial and the
subsequent follow‐up, and to compare our data with the US
X:BOT study. This analysis was performed focusing on the
risk of relapse to indicate a more nuanced representation of
illicit opioid use than reporting days of use. This approach
will provide clinicians with an added understanding of
relapse in these treatment trajectories and between the
treatment groups.
Further, we investigated if the risk of the first relapse
could be a clinically useful outcome measure to evaluate
the effectiveness of this treatment both in the randomized
12‐week trial and the subsequent 36‐week follow‐up period.
MATERIALS AND METHODS
Methods
This study is a 12‐week multicenter, open‐label,
randomized treatment study with a subsequent 36‐week
open‐label follow‐up study.9 The modified intention‐to‐treat
population included in the study (n= 143) had completed
detoxification and received at least one dose of study
medication, and had at least one valid assessment after
randomization. Due to the difference in detoxification
protocol between the two studies, the modified intention‐to‐
treat population was chosen to match the per protocol
population in the US X:BOT study. The modified intention‐
to‐treat population includes all patients randomized to
treatment who received at least one dose of study
medication and who had at least one valid assessment after
randomization. Allocation to treatment group was
computerized using a permuted block algorithm provided
by the regional monitoring authority and not stratified for site
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FIGURE 1. Kaplan‐Meier curve presenting
time to first relapse to all illicit opioids,
including heroin in XR‐NTX and BP‐NLX
groups. The first 12 weeks represent the
trial period and weeks 12 to 48 represent
the follow‐up period, where those
continuing XR‐NTX are compared with
those switching from BP‐NLX to XR‐
NTX. BP‐NLX = buprenorphine‐naloxone;
XR‐NTX = extended‐release naltrexone.
or sex. Randomization was performed as a 1:1 ratio in
balanced blocks to receive 380 mg XR‐NTX intramuscularly
every fourth week or daily sublingual BP‐NLX, 8‐24/2‐6 mg
(Fig. 1). Relapse was defined as 4 consecutive weeks of any
heroin or nonstudy opioid use or 7 consecutive days of heroin
or nonstudy opioid use. Relapse was censored at the end
of every 4‐week period. To maximize the accuracy of
such retrospective interview data, we used the Time‐Line
Follow‐Back data collecting method.10
Patients on BP‐LNX underwent detoxification by a
gradual tapering over a period of 7 days. They were in a
controlled environment for a minimum of 72 hours between
the last dose of BP‐NLX and the XR‐NTX injection. Just
before the first injection, a dose (0.4 mg) of the short‐acting
opioid antagonist naloxone was administered to test if
XR‐NTX could induce possible unacceptable withdrawal
symptoms. If so happened, the XR‐NTX injection would
be postponed for 24 hours. Upon entering the 9‐month
follow‐up period, patients could choose between BP‐NLX
and XR‐NTX. Of the 122 patients who entered the follow‐up,
only five chose to continue with BP‐NLX. Due to the low
number of BP‐NLX patients, no meaningful clinical or
statistical comparisons between the treatment groups could
be performed. These five BP‐NLX participants were
therefore excluded from further analyses.
The primary outcome variable was the time to first relapse
to heroin or other illicit opioid use in the randomized
12‐week period. The secondary outcome was the risk of any
relapse to heroin or other illicit opioid use in the randomized
part of the study and the risk of any relapse in the 36‐week
follow‐up study. The patients were not excluded from further
analyses in case of relapse. After the 12‐week trial period, all
participants entering the 36‐week prospective follow‐up
period chose XR‐NTX except five participants who chose
to continue with BP‐LNX. No participants switched from
XR‐NTX to BP‐LNX. Due to this distribution of participants
in the follow‐up period, we left the original trial design and
used a cohort design instead. Patients provided written
informed consent. They were not paid or compensated for
taking part in the study, with the exception of reimbursement
of travel expenses using public transportation.
Participants and Setting
Eligible patients were opioid‐dependent (Diagnostic
and Statistical Manual of Mental Disorders [DSM‐IV],
4th edition, 2000)11 men and women 18 to 60 years old.
Criteria for exclusion were pregnancy, lactation, acute
alcoholism, and severe somatic or psychiatric illness
interfering with study participation, such as decompensated
hepatic cirrhosis, renal failure, HIV with related symptoms,
current or recurrent affective disorders with suicidal behavior
and/or psychotic disorders. Women of childbearing age were
required to use contraceptive methods. Study personnel
screened patients for psychiatric disorders using the
M.I.N.I. Interview 6.012, while a physician examined
the patients for severe somatic disease. If necessary, eligible
patients were referred to the detoxification unit following
the screening. The design of the study, including sample size
calculation, is described in detail elsewhere.9 At inclusion and
every 4 weeks, patients underwent a structured interview
using the European version of the Addiction Severity Index.
The scores of the EuropASI in the domains of physical and
mental health, work, education, criminal activity, and social
functioning were similar at inclusion between the treatment
groups.10,13
In the randomized part of the study, weekly urine drug
tests (UDTs) were obtained, but not in the follow‐up study. In
a previous paper, we showed that the UDTs corresponded
well with patients’ report of illicit opioid use,7 and UDTs
were therefore not included in this paper.
Patients were recruited between November 1, 2012 and
July 10, 2015 from outpatient clinics and detoxification units
at five urban addiction clinics in Norway. All the patients
were invited to participate in the subsequent follow‐up study,
during which they could opt for one or the other medication
for an additional period of 36 weeks. The patients were
randomized after the end‐stage of detoxification. The study
was funded by The Research Council of Norway, The
Western Norway Regional Health Trust, and The Norwegian
Centre for Addiction Research and participating hospitals.
The study was approved by the South‐East Regional Ethical
Board for Medical Research Ethics (#2011/1320), the
Norwegian Medicines Agency, and by the Boards of
Research Ethics at every participating hospital.
Statistical Analysis
Baseline characteristics were described as means and SD
or frequencies and percentages. The number and percentage
of relapses as well as mean (SD) time to relapse to heroin and
other illicit opioids was presented for each week. All
numbers were presented by treatment group in the
randomised controlled trial period and by those continuing
or switching to XR‐NTX in the follow‐up period. The
retention between the treatment groups was compared by the
log‐rank test. Since the participants may either have no
relapses or one or more relapses, two types of analysis were
performed. The risk of the first relapse between the groups
was compared using the Cox regression model. To assess the
differences between the groups in risk of any relapse, an
extended Cox regression model adjusting for within‐patient
correlations occurring due to repeated measurements was
estimated. The results were presented as hazard ratios (HR)
with 95% confidence intervals (CI) and P values. Since the
use of illicit opioids, injecting days, mental health, self‐
assessed problematic drug use, alcohol abuse, cannabis use,
use of amphetamines and benzodiazepines, and Norwegian
kroner used on drugs last 30 days prior to inclusion might be
confounding characteristics; the sensitivity analyses adjusting
the HRs for these variables were carried out.23 The results
with P values below .05 were considered statistically
significant in all analyses. The analyses were performed in
SPSS version 25 and SAS version 9.4 (Table 1).
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RESULTS
The study included 143 patients who had successfully
completed detoxification, 37 women and 106 men. The mean
age was 35.7 (SD, 8.3) years in the XR‐NTX group and
35.9 (SD, 8.9) years in the BP‐NLX group.
In the 12‐week trial, the mean follow‐up time for the
XR‐NTX group was 10.8 (SE= 0.3) weeks and 10.6 (SE= 0.3)
weeks for the BP‐NLX group (P= .251 for the log‐rank test). In
the 36‐week prospective follow‐up period, the mean follow‐up
time for those who continued on XR‐NTX was 37.5 (SE= 1.6)
weeks and 37.1 (SE= 1.6) weeks for those who switched to
XR‐NTX after the trial period.
The risk of the first relapse to heroin and other illicit opioids
was reduced by 54% and 89% in the XR‐NTX group compared
to the BP‐NLX group (HR, 0.46; 95% CI, 0.28‐0.76; P= .002,
and HR, 0.11; 95% CI, 0.04‐0.27; P< .001), respectively (see
Table 2 and Fig. 2). The risk of any relapse to heroin or other
illicit opioids was also significantly reduced in the XR‐NTX
group compared to the BP‐NLX group (HR, 0.15; 95% CI,
0.09‐0.27; P< .001 and HR, 0.05; 95% CI, 0.03‐0.09;
P< .001, respectively), with a total of 14 and 11 relapses,
respectively, in the XR‐NTX group and 95 and 147 relapses,
respectively in the BP‐NLX group (P< .001 both groups). The
pooled risk of first or any relapse to any illicit opioids strongly
favored XR‐NTX (HR, 0.35; 95% CI, 0.22‐0.55; P< .001 and
HR, 0.08, 95% CI, 0.05‐0.12; P< .001, respectively) (Table 2
and Fig. 2). Adjustment for possible confounders assessed prior
to inclusion did not alter the results.
The 36‐week follow‐up study period included 117 patients
receiving XR‐NTX. There was no significant difference in
time to first relapse to heroin or other illicit opioids between
those continuing with XR‐NTX treatment and those switching
to XR‐NTX after week 12. Among those who continued to use
XR‐NTX, there were 27 relapses to heroin compared with 29
relapses among those switching to XR‐NTX. In both groups,
there were 18 relapses to other illicit opioids in the 36‐week
follow‐up (see Supporting Information). However, in the
group switching to XR‐NTX, there were more relapses to
other illicit opioids during the first four weeks compared to the
group continuing on XR‐NTX (HR, 0.45; 95% CI, 0.22‐0.94;
P= .034) despite the equal number of relapses in the two
groups throughout the study period (Table 2). On the other
hand, this difference between the groups became insignificant
after adjustment for the use of illicit opioids, injecting days,
mental health, self‐assessed problematic drug use, alcohol
abuse, cannabis use, use of amphetamines and benzo-
diazepines, and money (Norwegian kroner) used on drugs
assessed prior to baseline. Patients receiving XR‐NTX and
BP‐NLX displayed a similar retention time in the study, with
56 of the 71 patients in the XR‐NTX group and 49 of the 72 in
the BP‐NLX group completing the trial. The mean follow‐up
time for those who continued on XR‐NTX was 37.5 (SE= 1.6)
weeks and 37.1 (SE= 1.6) weeks for those who switched to
XR‐NTX after the randomized period (P= .642 for the log‐
rank test).
DISCUSSION
This study showed that opioid‐dependent patients who had
successfully completed detoxification and were randomized
to treatment with XR‐NTX had a substantially reduced risk of
relapse to heroin and other illicit opioids compared to those
randomized to BP‐NLX. The overall risk of relapse to any
illicit opioids was about three times in favor of treatment with
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TABLE 1. Demographic and baseline clinical characteristics of patients randomized to treatment with extended‐release naltrexone or






Sex (% male) 55 (78) 51 (71)
Injecting substances, raw numbers 66 66
Years with injections, mean (median) 9.9 (7.0) 9.9 (7.5)
Years of heroin use 6.2 (5.5) 7.0 (5.0)
Years of other heavy opioid use 8.4 (7.5) 8.5 (7.0)
Overdose events lifetime 4.5 (8.2) 4.4 (5.5)
Age at inclusion 35.7 (8.3) 35.9 (8.9)
Injecting days last 30 days at inclusion 9.2 (12.2) 11.4 (12.8)
Illicit opioids last 30 days at inclusion 8.2 (11.1) 14.2 (13.1)
Mental health (SCL 25) last 30 days at inclusion 47.3 (18.3) 49.8 (16.3)
Self‐assessed problem drug use last 30 days at inclusion 20.1 (13.0) 21.9 (12.2)
Alcohol abuse days last 30 days at inclusion 1.0 (3.9) 1.7 (5.3)
Cannabis use last 30 days at inclusion 7.7 (11.1) 10.9 (12.7)
Amphetamines days use last 30 days at inclusion 3.3 (7.1) 5.6 (9.3)
Benzodiazepines days use last 30 days inclusion 8.4 (11.3) 12.6 (13.0)
NKR used on drugs last 30 days at inclusion 7448 (12,700) 9567 (14,113)
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TABLE 2. Cox regression for risk of first relapse and risk of any relapse, to heroin, other illicit opioids and all illicit opioids, in the trial period and in
the 36‐week follow‐up
First relapse Any relapse
HR (95% CI) P value HR (95% CI) P value
Trial period
• Heroin
◦ BP‐NLX 1 1
◦ XR‐NTX 0.46 (0.28; 0.76) .002 0.15 (0.09; 0.27) <.001
• Other illicit opioids
◦ BP‐NLX 1 1
◦ XR‐NTX 0.11 (0.04; 0.29) <.001 0.05 (0.03; 0.09) <.001
• All illicit opioids
◦ BP‐NLX 1 1
◦ XR‐NTX 0.35 (0.22; 0.55) <.001 0.08 (0.05; 0.12) <.001
36‐week follow‐up
• Heroin
◦ Switched to XR‐NTX 1 1
◦ Continued XR‐NTX 0.78 (0.41; 1.50) .455 1.06 (0.62; 1.83) .830
• Other illicit opioids
◦ Switched to XR‐NTX 1 1
◦ Continued XR‐NTX 0.27 (0.07; 1.04) .057 0.45 (0.22; 0.94) .034
• All illicit opioids
◦ Switched to XR‐NTX 1 1
◦ Continued XR‐NTX 0.70 (0.36; 1.38) .305 0.85 (0.54; 1.34) .480
Bolded data indicate statistical significance P≤ .05.
CI= confidence interval; HR= hazard ratio.
FIGURE 2. Kaplan‐Meier curve presenting
time to first relapse to heroin in XR‐NTX
and BP‐NLX groups. The first 12 weeks
represent the trial period and weeks 12 to
48 represent the follow‐up period, where
those continuing XR‐NTX are compared
with those switching from BP‐NLX to XR‐
NTX. BP‐NLX = buprenorphine‐naloxone;
XR‐NTX = extended‐release naltrexone.
XR‐NTX. Our finding of low relapse rate to heroin and other
illicit opioids found in the XR‐NTX group is consistent with
other treatment studies of XR‐NTX.14‐16
Treatment with XR‐NTX reduces the use of illicit opioid
use more than does placebo or treatment referral, but the need
to withdraw from opioids before initiating XR‐NTX limits
its use. Approximately 37% of the study participants
withdrawing from opioids before XR‐NTX induction did
not start treatment.17‐19 Morgan et al20 notes that XR‐NTX
patients more often discontinued therapy compared to
BP‐NLX patients. This illustrates that the retention of
opioid‐dependent patients on XR‐NTX medication is a
challenge. In order not to limit the impact of a new opioid
addiction medication like XR‐NTX, methods for improving
retention rates are vital. It is further critically important to
determine the method that best could successfully increase
retention on XR‐NTX medication, and at the same time,
minimize withdrawal symptoms and risk of potential
relapse.21 In our study,22 we found that 49.6% of the
participants completed the 36‐week follow‐up with XR‐NTX,
which is within the range of findings in studies of OMT.
In our previous study, the objective was to determine
whether treatment with XR‐NTX would be as effective as
daily BP‐NLX in maintaining abstinence from heroin and
other illicit substances in newly detoxified patients. The
outcome was assessed in terms of days of use of illicit
opioids and confirmed by weekly UDTs, and the results
from these primary analyses were in accordance with the
secondary analyses in this study, but here the differences
between the groups were more accentuated. However, our
secondary analyses are not in line with the findings in the
US X:BOT study that reported an even relapse rate
(P = .44) between the two treatments after 24 weeks, even
in their per protocol population. Since the risk of relapse
may increase with time, we also compared our data to the
number of relapses after 12 weeks in the X:BOT study,
analyzed and given to us by the X:BOT study group for
this purpose (see the “Acknowledgments” section). This
12‐week analysis (data withheld) showed a similar robust
difference in relapse rate in XR‐NTX‐treated patients
between the studies as the previously published 24‐week
data. The substantial difference in relapse risk between the
studies therefore could not be attributed to the difference in
treatment time.8 We cannot explain this difference between
the United States and Norwegian studies regarding the risk
of relapse on XR‐NTX treatment, and further pooled
analyses should be performed on data from the two
studies. Since these studies may influence clinicians in
their choice of clinical treatment for opioid‐dependent
patients and their attitude toward XR‐NTX and BP‐NLX, it
seems important to further investigate this reported clinical
discrepancy in effectiveness.
It was only through participating in this study patients
could get access to XR‐NTX medication, and certainly,
most of the patients joined this study because they were
motivated to receive treatment with nonopioid medication
such as XR‐NTX to avoid the stigma and schemes
associated with the available opioid‐based medication.
This is an important consideration in clinical practice
when deciding on treatment in collaboration with patients
with opioid dependence. To optimize future treatment
with XR‐NTX, it seems vital to capture the patients’
perspectives on enablers and barriers to longer‐term
abstinence from opioids. For opioid‐dependent patients,
who could successfully complete detoxification and are
striving for abstinence from opioids, XR‐NTX could be
offered as a first‐line treatment.
Our main hypothesis for the better outcome on XR‐NTX
in Norway is the difference in the healthcare system between
the two countries. The Norwegian OMT program is publicly
funded with a choice of medication carrying no additional
cost to the patient. The Norwegian patients entered the study
primarily to get the novel XR‐NTX treatment. Maybe the US
patients were interested in joining the X:BOT study in order
to get OMT for their dependence, and not particularly
abstinent‐minded or seeking an antagonist treatment. This
might have influenced the results in favor of XR‐NTX in
Norway. The aspect of motivation for opioid abstinence
should be taken into consideration in clinical practice when
deciding on treatment for individuals with opioid
dependence. For opioid‐dependent individuals who could
successfully complete detoxification and who are motivated
for longer‐term abstinence from opioids, XR‐NTX could be
offered as a first‐line treatment.
Another issue raised by this study is whether relapse to
opioids is a clinically meaningful assessment to guide
clinicians in their choice of treatment. In our first paper, we
reported a moderate superiority of XR‐NTX over BP‐NLX
in the number of days of illicit opioid use, but the
magnitude of the difference between groups was far less
than the robust differences in relapse rates. The robust
difference between groups may, at least in part, be due to
how the relapse was defined, and a slightly modified
definition of relapse would probably have resulted in a
more moderate difference between the groups. We
therefore question the use of relapse rate as meaningful
guidance to clinicians in medication treatment choices for
patients with opioid dependence. Actually, a high number
of our patients that relapsed only once were highly
motivated for opioid abstinence and completed the full
study length.
Our inclusion and exclusion criteria of patients
corresponded well with those used in the US X:BOT
study, making the comparison valid for this population of
opioid‐dependent individuals. The US X:BOT study had
many dropouts due to failed detoxification, which led to
the superiority of BP‐NLX over XR‐NTX in the ITT
population analyses. The per protocol population,
however, showed an equal relapse rate between the
treatment groups. In contrast, our patients were included
at all stages of detoxification, but the majority after
having completed detoxification.
458 Extended‐Release, Heroin, Injectable, Medication‐Assisted, Naltrexone, Opioid Use Disorder September 2021
The low relapse rate of heroin and other illicit opioids on
XR‐NTX treatment was continued throughout the 36‐week
follow‐up period. The lack of difference in relapse rate
between those continuing with XR‐NTX and those switching
to XR‐NTX indicated that the relapse rate to any opioids was
low already from the first weeks of treatment and continued
to remain stable over time. When adjusted for current
symptoms of anxiety or depression, there was practically no
relapse to opioids after 24 weeks among participants with low
or no symptoms of anxiety or depression.14 The effects of
XR‐NTX in reducing the risk of relapse to heroin and other
illicit opioids were upheld by those continuing and those who
switched to XR‐NTX.
Extended‐release formulations of buprenorphine could
have been a more relevant comparator for XR‐NTX than
oral daily BP‐NLX since this formulation may provide
protection against diversion and improve patient
compliance However, extended‐release buprenorphine
was not approved in Europe until 2019, and such a
comparison have not yet been systematically evaluated.
Further research should conduct a comparative
effectiveness study of XR‐NTX versus extended‐release
buprenorphine.17
Limitations
The lack of blinding in our study represents a
limitation; however, the effect sizes are beyond what
usually could be expected from placebo effects. Another
limitation is that the reported opioid use was not
confirmed by UDT in the follow‐up part of the study.
However, in the 12‐week period, reported use of opioids
corresponded well with the UDTs results.7 Another
consideration is the possible reduced generalizability to
opioid‐dependent patients at large since XR‐NTX was
available only through participation in the study, and BP‐
NLX was accessible in OMT programs. The patients in
this study were probably more motivated toward opioid
abstinence than the average population of opioid‐
dependent individuals, and this may have influenced the
outcome. However, in the randomized part of the study,
such a motivation not to use illicit opioids should also be
relevant for those randomized to 12 weeks of BP‐NLX.
CONCLUSIONS
In line with our descriptive data, relapse analyses
showed that XR‐NTX was clearly more efficacious in
preventing relapse to heroin and other illicit opioid use
compared to BP‐NLX, in contrast to the US X:BOT study
showing an equal rate of relapse between treatments. The
low relapse rate for XR‐NTX patients continued
throughout the follow‐up period. Our data indicate that
XR‐NTX should be proposed as a first‐line treatment
option for abstinence‐motivated patients with opioid
addiction. Further, the level of motivation for XR‐NTX
should be taken into consideration when deciding on
treatment modality in clinical practice.
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